Arai et al., 1995 - Google Patents

Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease

Arai et al., 1995

Document ID
17221451551176345647
Author
Arai H
Terajima M
Miura M
Higuchi S
Muramatsu T
Machida N
Seiki H
Takase S
Clark C
Lee V
Trojanowski J
Sasaki H
Publication year
Publication venue
Annals of Neurology: Official Journal of the American Neurological Association and the Child Neurology Society

External Links

Snippet

Cerebrospinal fluid from 70 patients with Alzheimer's disease (AD) and 96 patients with non‐ AD neurological diseases as well as 19 normal control subjects was surveyed by sandwich enzyme‐linked immunosorbent assay to quantitate levels of the microtubule‐associated …
Continue reading at onlinelibrary.wiley.com (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2828—Prion diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—G01N2333/4701
    • G01N2333/4709—Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Similar Documents

Publication Publication Date Title
Arai et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease
US6680173B2 (en) Diagnosis of tauopathies
Blennow et al. Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?
Hesse et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke
Sennvik et al. Levels of α-and β-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients
Foulds et al. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies
Zetterberg et al. Increased cerebrospinal fluid levels of transforming growth factor-β1 in Alzheimer’s disease
Öhrfelt et al. Cerebrospinal fluid α-synuclein in neurodegenerative disorders—a marker of synapse loss?
US5270165A (en) Method of diagnosis of amyloidoses
US5601985A (en) Method of detecting abnormally phosphorylated tau(τ)
Lau et al. The existence of Aβ strains and their potential for driving phenotypic heterogeneity in Alzheimer’s disease
ES2264691T3 (en) EARLY DIAGNOSIS OF CONFORMATIONAL DISEASES.
McGeer et al. Immunohistochemical localization of beta‐amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy
Skoog et al. A population-based study of tau protein and ubiquitin in cerebrospinal fluid in 85-year-olds: relation to severity of dementia and cerebral atrophy, but not to the apolipoprotein E4 allele
Wischik et al. Quantitative analysis of tau protein in paired helical filament preparations: implications for the role of tau protein phosphorylation in PHF assembly in Alzheimer's disease
Arai et al. Apolipoprotein E genotyping and cerebrospinal fluid tau protein: implications for the clinical diagnosis of Alzheimer’s disease
EP1131635A1 (en) An immunoassay for the determination of transmissible spongiform encephalopathies in bovine
Mehta Amyloid beta protein as a marker or risk factor of Alzheimer's disease
Yamada et al. Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy
Yokota et al. Variability and heterogeneity in Alzheimer's disease with cotton wool plaques: a clinicopathological study of four autopsy cases
Ono et al. Cerebrospinal fluid of Alzheimer patients promotes β-amyloid fibril formation in vitro
Riemenschneider et al. Association of CSF apolipoprotein E, Aβ42 and cognition in Alzheimer’s disease
US20210270848A1 (en) Method for diagnosing dementia or determining the risk of developing dementia
EP1135687A1 (en) An immunoassay for the determination of transmissible spongiform encephalopathies in mammals
Defossez et al. Transformation of degenerating neurofibrils into amyloid substance in Alzheimer's disease: histochemical and immunohistochemical studies